We propose a multidisciplinary research training program in clinical neuro-oncology based at the Massachusetts General Hospital. The primary objective of this two year program is to train physician- scientists capable of providing a critical bridge between brain tumor biology and experimental therapeutics. In order to achieve this objective the training program emphasizes a didactic curriculum in clinical research methodology, cancer cell biology and cancer pharmacology as well as mentor-supervised laboratory and clinical research experience. All clinical and laboratory mentors participating in this training program have extensive experience in neuro-oncology research and training and provide an excellent resource for trainees interested in translational research. All trainees will also have access to senior biostatistical and computing support on all projects. An advisory committee headed by the program director will oversee the training program. In addition to clinical and basic science research facilities at the Massachusetts General Hospital participating institutions include the Brigham and Women's Hospital and the Dana- Farber Cancer Institute. Candidates will include physicians completing clinical training in neurology, neurosurgery, medical oncology and radiation oncology. A qualified pool of applicants from these disciplines can be expected from existing and developing sources. Each trainee will have a dedicated two- year block for research and training with minimal clinical responsibilities. Four postdoctoral positions are requested per year for five years with each trainee making a two year commitment to investigation. Applicants will be selected through active recruitment by the program and individual faculty. We believe that the proposed training program capitalizes on an existing group of outstanding mentors and superb training facilities and will capability to produce productive clinician scientists in neuro-oncology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA090354-03
Application #
6654921
Study Section
Subcommittee G - Education (NCI)
Program Officer
Lei, Ming
Project Start
2001-09-26
Project End
2006-08-31
Budget Start
2003-09-01
Budget End
2004-08-31
Support Year
3
Fiscal Year
2003
Total Cost
$432,996
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Hess, Clayton B; Indelicato, Daniel J; Paulino, Arnold C et al. (2018) An Update From the Pediatric Proton Consortium Registry. Front Oncol 8:165
Andronesi, Ovidiu C; Arrillaga-Romany, Isabel C; Ly, K Ina et al. (2018) Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun 9:1474
Miller, Julie J; Wick, Wolfgang (2018) What's New in Grade II and Grade III Gliomas? Semin Neurol 38:41-49
Wang, Nancy; Bertalan, Mia S; Brastianos, Priscilla K (2018) Leptomeningeal metastasis from systemic cancer: Review and update on management. Cancer 124:21-35
Filbin, Mariella G; Tirosh, Itay; Hovestadt, Volker et al. (2018) Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science 360:331-335
Wang, Nancy; Osswald, Matthias (2018) Meningiomas: Overview and New Directions in Therapy. Semin Neurol 38:112-120
Tateishi, Kensuke; Higuchi, Fumi; Miller, Julie J et al. (2017) The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity. Cancer Res 77:4102-4115
Venteicher, Andrew S; Tirosh, Itay; Hebert, Christine et al. (2017) Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science 355:
Brastianos, Priscilla K; Shankar, Ganesh M; Gill, Corey M et al. (2016) Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. J Natl Cancer Inst 108:
Kloepper, Jonas; Riedemann, Lars; Amoozgar, Zohreh et al. (2016) Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A 113:4476-81

Showing the most recent 10 out of 45 publications